Patents by Inventor Steven Sheriff
Steven Sheriff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11708405Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: December 27, 2019Date of Patent: July 25, 2023Assignee: BRISTOL-MYERS QUIBB COMPANYInventors: Mohan Srinivasan, Shrikant Deshpande, Qihong Zhao, Huadong Sun, Ginger Rakestraw, Guodong Chen, Richard Y. Huang, Steven Sheriff, Cristian Rodriguez, John P. Throup, Rose A. Dibella
-
Publication number: 20220220220Abstract: The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.Type: ApplicationFiled: January 7, 2022Publication date: July 14, 2022Inventors: Joseph M. Luettgen, Lumelle Schneeweis, Ginger Chao Rakestraw, Christina Terragni, Andrew Karl Dilger, Jason Robert Pinckney, Steven Sheriff, Kevin Kish, Yongmi An, William R. Ewing, Stanley Richard Krystek, JR., Aaron Paul Yamniuk
-
Patent number: 11136406Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: GrantFiled: December 20, 2019Date of Patent: October 5, 2021Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
-
Publication number: 20200199244Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: ApplicationFiled: December 20, 2019Publication date: June 25, 2020Inventors: Anish SURI, Steven SHERIFF, Suzanne SUCHARD, Aaron YAMNIUK, Stanley KRYSTEK, James TAMURA, James BRYSON, Steven GRANT, Philip DREW
-
Publication number: 20200190180Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: ApplicationFiled: December 27, 2019Publication date: June 18, 2020Inventors: Mohan SRINIVASAN, Shrikant DESHPANDE, Qihong ZHAO, Huadong SUN, Ginger RAKESTRAW, Guodong CHEN, Richard Y. HUANG, Steven SHERIFF, Cristian RODRIGUEZ, John P. THROUP, Rose A. DIBELLA
-
Patent number: 10556948Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: November 30, 2016Date of Patent: February 11, 2020Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Mohan Srinivasan, Shrikant Deshpande, Qihong Zhao, Huadong Sun, Ginger Rakestraw, Guodong Chen, Richard Y. Huang, Steven Sheriff, Cristian Rodriguez, John P. Throup, Rose A. Dibella
-
Patent number: 10544228Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: GrantFiled: September 8, 2016Date of Patent: January 28, 2020Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
-
Publication number: 20170158757Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: ApplicationFiled: November 30, 2016Publication date: June 8, 2017Inventors: Mohan SRINIVASAN, Shrikant DESHPANDE, Qihong ZHAO, Huadong SUN, Ginger RAKESTRAW, Guodong CHEN, Richard Y. HUANG, Steven SHERIFF, Cristian RODRIGUEZ, John P. THROUP, Rose A. DIBELLA
-
Publication number: 20170015754Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: ApplicationFiled: September 8, 2016Publication date: January 19, 2017Inventors: Anish SURI, Steven SHERIFF, Suzanne SUCHARD, Aaron YAMNIUK, Stanley KRYSTEK, James TAMURA, James BRYSON, Steven GRANT, Philip DREW
-
Patent number: 9475879Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: GrantFiled: April 20, 2012Date of Patent: October 25, 2016Assignees: BRISTOL-MYERS SQUIBB COMPANY, DOMANTIS LIMITEDInventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
-
Patent number: 9260496Abstract: The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (IL-23). The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: GrantFiled: December 20, 2011Date of Patent: February 16, 2016Assignee: Bristol-Myers Squibb CompanyInventors: Ruchira Dasgupta, Steven Sheriff, Anzhi Wei, Vidhyashankar Ramamurthy, Alex Bush, Katie A. Russo, Linda Engle
-
Publication number: 20150086552Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.Type: ApplicationFiled: May 21, 2013Publication date: March 26, 2015Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty, Milan Gao, Steven Sheriff, Noah Ditto, Nels B. Hamacher
-
Publication number: 20140099317Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: ApplicationFiled: April 20, 2012Publication date: April 10, 2014Applicants: DOMANTIS LIMITED, BRISTOL-MYERS SQUIBB COMPANYInventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
-
Publication number: 20130288372Abstract: The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (IL-23). The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: December 20, 2011Publication date: October 31, 2013Inventors: Ruchira Dasgupta, Steven Sheriff, Anzhi Wei, Vidhyashankar Ramamurthy, Alex Bush, Katie A. Russo, Linda Engle
-
Publication number: 20020068346Abstract: The present invention provides isolated modified inosine 5′-monophosphate dehydrogenase (IMPDH) polypeptides. These modified IMPDH polypeptides comprise a substitute oligo-peptide that replaces the subdomain region. The modified polypeptides of the invention bind to an inhibitor, such as MPA, and/or exhibit functional activity of wild-type IMPDH holo-enzyme.Type: ApplicationFiled: May 10, 2001Publication date: June 6, 2002Inventors: Stanley R. Krystek, Steven Sheriff, Mark R. Witmer, Diane L. Hollenbaugh, Ning Yan, Julie E. Mouravieff, Howard M. Einspahr, Kevin Kish